DENVER–(BUSINESS WIRE)–Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or “the Company”) today announced Nirup Krishnamurthy has joined the Company as Chief Integration and Information Officer, reporting directly to Justin Dye, Chief Executive Officer.
In this newly created role, Krishnamurthy will lead the integration of the Company’s outlined acquisitions, any future acquisitions and the realization of identified integration synergies. In addition to integration responsibilities, Krishnamurthy will lead Medicine Man Technologies’ IT strategy and operations, implementing business solutions to empower real-time, data-driven decisions and ensure the security and stability of the Company’s infrastructure.
“Nirup’s ability to unlock business value while accelerating growth are key advantages he brings to Medicine Man Technologies,” said Justin Dye, Chief Executive Officer. “His experience and leadership coupled with deep capabilities in both technology and integration spaces, are those that I have been able to experience first-hand during our partnership at Dye Capital. With Medicine Man Technologies’ announced acquisition strategy, deliberate technology and integration are critical tenets to ensuring our combined company is successful. Nirup has successfully guided complex, global companies through transformations and I look forward to having his keen focus and detailed approach at Medicine Man Technologies.”
“I am thrilled to be part of this one in a lifetime opportunity at Medicine Man Technologies to help develop the most admired cannabis company in the world,” Nirup Krishnamurthy shared. “It is not often that one gets to design and build a growth platform from the ground up and integrate companies effectively. As the Company brings together some of the best operators across the state, Medicine Man Technologies is poised to become a global leader and I look forward to participating in the explosive growth of this emerging industry.”
Krishnamurthy has over 25 years of experience in innovation, technology, integration, restructuring and M&A at Fortune 500 companies. As Chief Information Officer of United Airlines, Krishnamurthy was part of the management team that undertook one the largest turnaround restructurings in corporate America. He used technology, business analytics and process improvements as major levers to drive cost reduction and revenue enhancement for the airline. After United Airlines, Krishnamurthy became Chief Technology Officer and Executive Vice President at Northern Trust Bank where he oversaw an IT Transformation effort that enabled better collaboration and implemented several large-scale enterprise wide initiatives. Krishnamurthy was also Chief Strategy Officer at The Great Atlantic & Pacific Company where he oversaw the operational restructuring and the subsequent M&A transaction. For the past several years, he has been a partner at Dye Capital and oversees its technology investment portfolio. Krishnamurthy holds an undergraduate degree in Mechanical Engineering and a Ph.D. in Industrial Engineering from SUNY at Buffalo.
For more information about Medicine Man Technologies, please visit https://www.MedicineManTechnologies.com
About Medicine Man Technologies
Denver, Colorado-based Medicine Man Technologies (OTCQX: MDCL) is a rapidly growing provider of cannabis consulting services, nutrients, and supplies. The Company’s client portfolio includes active and past clients throughout the cannabis industry in 20 states and seven countries. The Company has entered into agreements to become one of the largest vertically integrated seed-to-sale operators in the global cannabis industry. Current agreements will enable Medicine Man Technologies to offer cultivation, extraction, distribution and retail pharma-grade products. Management includes decades of cannabis experience, a unique combination of first movers in industrial cannabis and proven Fortune 500 corporate executives.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.